Long-term survival case of SCLC transformation after Osimertinib resistance in EGFR-mutant NSCLC: Benefits from chemo-immunotherapy combined with anti-angiogenic therapy followed by Osimertinib rechallenge
Cancer Lett. 2025 Mar 31:613:217474.
doi: 10.1016/j.canlet.2025.217474.
Epub 2025 Jan 23.
1 Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer(IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
2 Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer(IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China. Electronic address: junxy88@163.com.